Following the publication of new draft guidance by NICE on the care and management of osteoarthritis, Dr Fiona Watt breaks down the misconceptions surrounding its impact on patients and healthcare professionals, and why developing effective treatments for the condition is more vital than ever.
8.75 million people live with osteoarthritis in the UK and the condition is the fourth leading cause of years lived with disability worldwide. Osteoarthritis commonly affects joints such as the knee, hip or hand, leading to progressive change and damage in joint tissues, frequently causing joint pain and functional difficulties. It is the leading cause of joint replacement. As an osteoarthritis researcher and someone who treats people with osteoarthritis in the NHS, I awaited the draft updated National Institute for Health & Care Excellence (NICE) guidance on the management of osteoarthritis with some anticipation. This guidance is important because it shapes (and restricts) the way that the NHS approaches advice and treatment, based on scientific evidence.
This is an open letter from Mr Martin Lupton, Vice-Dean of Education to taught students in the Faculty of Medicine and their loved-ones.
Dear Students and their friends and families,
My eldest son has recently returned to University in the UK and, even though I work in both the health and education sector, I have to acknowledge that I have a certain level of anxiety about him. It is very difficult to read the news about all that has happened during this time of COVID and not to worry.
I am telling you this because I want you to understand that I have some inkling of what you may be feeling right now, particularly if you come from overseas or your daughter, son or relation, has just started their university life. The first thing I want to say is “Welcome to the Faculty of Medicine”. We are very proud of what we have achieved during this global pandemic; the Faculty of Medicine at Imperial College has been a key player contributing to the world’s understanding of the virus, the mapping of the virus, teaching people about the virus and developing a new vaccine. However, that is not all that we have been doing. (more…)
Professor Danny Altmann explores how the pandemic has offered new perspectives on his research, leading to new collaborations and engaging with policy.
If any of us ever wished for greater prominence, respect, or public understanding of our scientific contributions to society, this is not the way we would have wished to achieve it. For so many at Imperial working in diverse aspects of infection, immunity and global health, this has been a time of much urgent soul-searching as to how we can best bring our skill sets to bear on the problem most effectively, whether as clinicians, disease modellers, vaccinologists or basic immunologists. It’s hard to turn on a news broadcast or open a newspaper without seeing opinions from Imperial colleagues, clinical and scientific.
At a time when the mantra is ‘policy led by the science’, this is absolutely as it should be. We often have it ingrained as scientists to keep our heads down lest we be accused of showboating or playing ‘Johnny-Big-Potato’ by making inflated claims about our research. Yet, this is a time when it’s OK and even laudable to stick your head above the parapet: when it genuinely matters, and people genuinely want to know, what are these different types of antibody tests, is antibody protective and how long does it last, which may be the most effective vaccines. This surely is the time to step up to the plate, whether by adapting the research focus of our labs to the current issues, by communicating and trying to clarify the nuances, and of course, by remembering our commitments to our students and trying to work out how to keep them stimulated and scientifically productive despite lockdown. (more…)
PhD student Philippa May reflects on being a scientist in the field blood cancer, from working in a leukaemia diagnostic laboratory to a research laboratory.
For the last 10 years I have been a clinical scientist in genetics working across various London NHS Trusts. Whilst I loved diagnostics, last year I left my job to complete my PhD. I worked in a part of life sciences called cytogenetics. This meant when a patient was diagnosed with blood cancer, I would analyse their chromosomes – the structures into which DNA is organised – from their blood or bone marrow to look for specific abnormalities. For some patients, this can lead to a definitive diagnosis. For others a refined prognosis, and in some, it’s simply a way of monitoring how well the patient’s leukaemia is responding to their treatment. (more…)
In this post, four Imperial researchers write about the different ways in which Leuka has supported their work at the College.
Leuka is a charity that supports life-saving research into the causes and treatment of leukaemia and other blood cancers. Funding from dedicated charities such as Leuka provides an important source of support which enables high-quality research programmes here at Imperial to develop and progress. (more…)